Most medical technology entrepreneurs will tell you that in recent years, reimbursement has become as large of a barrier to successful commercialization as regulatory clearance. Medical device manufacturers that do not plan early for reimbursement risk prolonged delays in bringing products to the market as the FDA approval/clearance process is an extremely important, single, sentinel event.
In order to maximize resource efficiency and speed-to-market, medical organizations should begin reimbursement planning early and allow full integration into the associated regulatory and clinical planning.
Join us for this NAMSA webinar, presented by Edward Black, Director of Global Reimbursement Strategy, as we present information on:
Time will also be allotted for Q&A.
About the Presenter:
|Edward Black specializes in reimbursement strategy, payer relations and health economics for medtech and biotech companies in the U.S. and abroad. He works with medical device organizations to commercialize new products and services through successful reimbursement planning.
Prior to joining NAMSA in 2018, Mr. Black founded Reimbursement Strategies, LLC in 2008, a medtech consultancy focused on reimbursement services including HCPCS and CPT coding analysis and new code submissions; medical coverage policy research, analysis and advocacy; payment negotiation; clinical trial optimization for reimbursement and health economics for new and existing technologies.
Mr. Black also has 25 years’ experience in health and provider network management within the Blue Cross Blue Shield (BCBS) healthcare system and served on two national advisory boards responsible for leading consistency in medical, benefit, and payment policies. From 1994 to 2002, Edward served as the Executive Director of three managed care business partnerships with large multi-specialty clinics for which he was honored with the 1995 Outstanding Contribution to the Healthcare Industry Award by Medical Alley Association.
Mr. Black is active in several global medical technology initiatives and is a frequent international lecturer. He serves as an adjunct faculty member of the University of Minnesota Master of Science in Medical Device Innovation Program, and is a Reimbursement Advisor to the University of Minnesota Office for Technology Commercialization and National University of Ireland Galway BioExel Program.